Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SXTP 
60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: SXTP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7
1 Year Target Price $7
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -69.53% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.34M USD | Price to earnings Ratio 18.57 | 1Y Target Price 7 |
Price to earnings Ratio 18.57 | 1Y Target Price 7 | ||
Volume (30-day avg) 1 | Beta 2.71 | 52 Weeks Range 1.22 - 12.45 | Updated Date 08/29/2025 |
52 Weeks Range 1.22 - 12.45 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.07 |
Earnings Date
Report Date 2025-08-15 | When - | Estimate -0.1 | Actual -1.0817 |
Profitability
Profit Margin - | Operating Margin (TTM) -521.27% |
Management Effectiveness
Return on Assets (TTM) -113.11% | Return on Equity (TTM) -294.87% |
Valuation
Trailing PE 18.57 | Forward PE - | Enterprise Value 13090567 | Price to Sales(TTM) 5.42 |
Enterprise Value 13090567 | Price to Sales(TTM) 5.42 | ||
Enterprise Value to Revenue 20.41 | Enterprise Value to EBITDA 22.23 | Shares Outstanding 4104470 | Shares Floating 3728212 |
Shares Outstanding 4104470 | Shares Floating 3728212 | ||
Percent Insiders 2.9 | Percent Institutions 12.9 |
Upturn AI SWOT
60 Degrees Pharmaceuticals, Inc. Common Stock
Company Overview
History and Background
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for infectious diseases. Founded in 2010, it is dedicated to developing novel therapies and vaccines, especially for unmet medical needs in global health.
Core Business Areas
- Infectious Disease Therapeutics: Focuses on developing and commercializing treatments for infectious diseases, including malaria and other travel-related illnesses. Primarily devoted to the development and commercialization of Arakloda, a tafenoquine product to prevent malaria.
Leadership and Structure
The leadership team consists of experienced professionals in the pharmaceutical industry and global health. Specific organizational structure details are not widely available in public sources.
Top Products and Market Share
Key Offerings
- Arakloda: Arakloda (tafenoquine) is an FDA-approved medication for the prevention of malaria in adults. Market share data is not readily available. Competitors include drugs like Malarone, Lariam, and doxycycline. Market for anti-malarial drugs is driven by international travel and military deployments.
Market Dynamics
Industry Overview
The infectious disease therapeutics market is driven by increasing global travel, emerging infectious diseases, and antimicrobial resistance. There is significant investment in R&D for new treatments and vaccines.
Positioning
60 Degrees Pharmaceuticals is positioned as a specialty pharmaceutical company addressing unmet needs in the prevention of malaria. Their competitive advantage lies in their focus on specific infectious diseases and novel therapies.
Total Addressable Market (TAM)
The global antimalarial drug market is estimated to be over $1 billion. 60 Degrees Pharmaceuticals aims to capture a significant share of this market with Arakloda.
Upturn SWOT Analysis
Strengths
- FDA-approved product (Arakloda)
- Focus on unmet medical needs
- Specialty pharmaceutical expertise
Weaknesses
- Limited product portfolio
- Reliance on a single product (Arakloda)
- Limited public information about the financials
Opportunities
- Expansion into new markets (international travel)
- Development of new infectious disease therapies
- Partnerships and collaborations
Threats
- Competition from existing antimalarial drugs
- Generic drug entry
- Changes in travel patterns and disease prevalence
Competitors and Market Share
Key Competitors
- GSK (GSK)
- Sanofi (SNY)
- Mylan (MYL, now VTRS)
Competitive Landscape
60 Degrees Pharmaceuticals competes with larger pharmaceutical companies in the antimalarial market. Their strength lies in Arakloda, but they need to expand product portfolio to remain competitive.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data cannot be determined due to a lack of available public information.
Future Projections: Future growth projections are speculative without available financial data. Analyst estimates are not readily available.
Recent Initiatives: Focus on commercializing Arakloda and expanding its market reach, as well as any ongoing research to develop new therapies.
Summary
60 Degrees Pharmaceuticals is a specialty pharmaceutical company with a focus on infectious diseases, primarily malaria prevention. The company's strength lies in its FDA-approved product, Arakloda. However, its dependence on a single product and competition from larger pharmaceutical companies pose challenges, necessitating strategic initiatives to expand its portfolio and market presence. Financial details are difficult to confirm given the company is private.
Peer Comparison
Sources and Disclaimers
Data Sources:
- FDA website
- Company press releases
- Industry reports
Disclaimers:
This analysis is based on limited publicly available information and is subject to change. Financial data is not readily available, so certain aspects are based on estimates and industry trends.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About 60 Degrees Pharmaceuticals, Inc. Common Stock
Exchange NASDAQ | Headquaters Washington, DC, United States | ||
IPO Launch date 2023-07-12 | Chairman, CEO & President Dr. Geoffrey Stuart Dow Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://www.60degreespharma.com |
Full time employees 3 | Website https://www.60degreespharma.com | ||
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.